Veltuzumab

Veltuzumab is a monoclonal antibody (targeted at CD20) which is being investigated for the treatment of non-Hodgkin's lymphoma.[1][2] As of December 2011, it is undergoing Phase I/II clinical trials.[3] When used with milatuzumab it showed activity.[4]

Veltuzumab
Monoclonal antibody
TypeWhole antibody
SourceHumanized (from mouse)
TargetCD20
Clinical data
ATC code
  • none
Identifiers
CAS Number
ChemSpider
  • none
UNII
Chemical and physical data
FormulaC6458H9918N1706O2026S46
Molar mass145349.06 g·mol−1
 NY (what is this?)  (verify)

This drug was developed by Immunomedics, Inc. and was originally known as IMMU-106.[5]

In August 2015 the US FDA granted it orphan drug status for immune thrombocytopenia (ITP).[6] A phase II trial is planned to run for 5 years.[6]

See also
  • CD20 antagonist

References
  1. Statement On A Nonproprietary Name Adopted By The USAN Council - Veltuzumab, American Medical Association.
  2. Rossi EA, Goldenberg DM, Cardillo TM, Stein R, Chang CH (October 2009). "CD20-targeted tetrameric interferon-alpha, a novel and potent immunocytokine for the therapy of B-cell lymphomas". Blood. 114 (18): 3864–71. doi:10.1182/blood-2009-06-228890. PMC 2773491. PMID 19710501.
  3. Clinical trial number NCT00546793 for "Ph I/II Study of Subcutaneously Administered Veltuzumab (hA20) in NHL and CLL" at ClinicalTrials.gov
  4. Christian BA, Poi M, Jones JA, Porcu P, Maddocks K, Flynn JM, et al. (June 2015). "The combination of milatuzumab, a humanized anti-CD74 antibody, and veltuzumab, a humanized anti-CD20 antibody, demonstrates activity in patients with relapsed and refractory B-cell non-Hodgkin lymphoma". British Journal of Haematology. 169 (5): 701–10. doi:10.1111/bjh.13354. PMC 7297055. PMID 25847298.
  5. Zibelman M, Borghaei H, Olszanski AJ (2014). "Harnessing Innate Immunity". In Dubel S, Reichert JM (eds.). Handbook of Therapeutic Antibodies (2nd ed.). John Wiley & Sons. p. 791. doi:10.1002/9783527682423.ch27. ISBN 978-3-527-68244-7.
  6. "FDA grants orphan drug designation to veltuzumab for ITP". HemOnc Today. Healio.com. August 4, 2015.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.